Guobang Pharma (SH:605507)2023-04-14 16:00Financial Performance - Operating revenue for Q1 2023 was CNY 1,410,162,706.26, up from CNY 1,176,098,332.11 in Q1 2022, reflecting a significant increase[22] - The company's operating revenue for Q1 2023 was CNY 1,410,162,706.26, representing a year-on-year increase of 19.90%[37] - The company reported a net profit of CNY 2,603,706.71 after accounting for various income and tax impacts[15] - The net profit attributable to shareholders for Q1 2023 was CNY 194,629,337.80, a decrease of 2.88% compared to the same period last year[37] - The company reported a decrease in total profit for Q1 2023, amounting to CNY 228,633,029.61, down from CNY 235,103,308.71 in the same period last year[46] - The net profit attributable to the parent company's shareholders was approximately $194.63 million, a decrease from $200.39 million in the previous period, representing a decline of about 2.4%[60] - The total comprehensive income amounted to approximately $194.97 million, down from $200.31 million, indicating a decrease of around 2.9%[60] Cash Flow - Cash flow from operating activities surged by 207% due to a significant increase in sales receipts compared to the same period last year[16] - The net cash flow from operating activities for Q1 2023 was CNY 210,380,795.68, showing a significant increase of 207.00% year-on-year[37] - Cash inflow from operating activities for Q1 2023 was approximately $1.06 billion, an increase of 38.5% compared to $762.99 million in Q1 2022[48] - Net cash flow from operating activities reached $210.38 million, significantly up from $68.53 million in the same period last year, marking a growth of 206.5%[48] - The net cash flow from investing activities for Q1 2023 was CNY 60,442,955.33, a turnaround from a negative cash flow of CNY 25,669,620.90 in the previous year[37] - The net cash flow from financing activities for Q1 2023 was CNY 87,791,452.32, compared to CNY 28,188,852.11 in the same period last year[37] Assets and Liabilities - Total assets increased by 8.13% to CNY 9,778,471,788.41 compared to CNY 9,043,184,958.17 in the previous period[4] - Total liabilities increased to CNY 2,428,895,365.25 from CNY 1,888,579,890.48, reflecting higher financial obligations[11] - Deferred income decreased to CNY 13,732,704.21 from CNY 14,266,913.85, showing a reduction in liabilities[11] - Non-current assets totaled CNY 4,106,680,270.21, an increase from CNY 3,913,865,466.88[21] - Short-term borrowings rose to CNY 748,600,555.56 from CNY 655,569,791.66, indicating increased leverage[21] Shareholder Information - The company reported a total of 28,499 common shareholders at the end of the reporting period[54] - The largest shareholder, Xinchang Ande Trading Co., Ltd., holds 23.08% of the shares, totaling 128,951,976 shares[54] Earnings and Expenses - The basic earnings per share for Q1 2023 was CNY 0.35, reflecting a decrease of 2.78% compared to the previous year[37] - The company's research and development expenses for Q1 2023 amounted to CNY 46,857,324.22, an increase from CNY 31,655,326.74 in the previous year[46] - Basic and diluted earnings per share were both reported at $0.35, a slight decrease from $0.36 in the previous period[60] Cash and Inventory - The total cash and cash equivalents at the end of the period reached CNY 1,934,456,200.04, up from CNY 643,928,226.66 at the end of the previous year[37] - Total current assets as of March 31, 2023, were approximately $5.67 billion, an increase from $5.13 billion at the end of 2022, showing a growth of 10.6%[57] - Cash and cash equivalents stood at $2.56 billion, compared to $1.97 billion at the end of 2022, reflecting a growth of 29.6%[57] - Inventory levels increased to $1.46 billion from $1.41 billion, marking a rise of 3.5%[57] Cash Flow from Sales - Total cash received from the sale of goods and services was approximately $963.37 million, compared to $694.82 million in Q1 2022, reflecting a year-over-year increase of 38.7%[48] - Cash paid for purchasing goods and services amounted to $595.59 million, up from $462.93 million in Q1 2022, representing a rise of 28.6%[48] - Cash received from investment recoveries was $559.63 million, down from $1.15 billion in Q1 2022, indicating a decrease of 51.3%[48]